Meditation for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Meditation for Health & Longevity

Created on 09/09/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Meditation is a trainable attention skill, not a treatment. The most consistent effects — less anxiety and low mood, better self-reported sleep, calmer blood pressure, less suffering from long-standing pain — are real but modest, and shrink against another active practice. The claims that reach furthest rest on the weakest footing. Harms are neither rare nor, for most people, severe. (Full Review)

Protocol

Standard course (Kabat-Zinn, University of Massachusetts)
8 weekly 2.5-hour classes
Mindfulness-based stress reduction: one 6-hour silent day plus 45 minutes of daily home practice.
Minimum effective dose
13 minutes daily
Improved mood, attention, working memory and stress reactivity at eight weeks but not at four, in meditation-naive adults.
Single session or split sessions
20–45 min, or 2 × 10–20 min
Total accumulated minutes, not distribution, tracks with measured outcomes.
Time to effect
Anxiety and depressive symptoms
8 weeks
Mood changes emerged at eight weeks but not at four; effects persist at three to six months.
Blood pressure and heart rate
Single session
Acute falls persist a few hours; durable change requires sustained daily practice.
Sleep quality
6–8 weeks
Improves in adults with existing sleep disturbance; against an established sleep treatment it is indistinguishable from zero.

Benefits

Contraindications
  • Active psychosis, or a schizophrenia-spectrum diagnosis with symptoms in the past 12 months (intensive formats: over 4 hours daily, or any silent retreat)
  • Current manic or hypomanic episode, or bipolar I disorder that is not pharmacologically stabilized
  • Acute suicidal crisis (active ideation with plan or intent, until stabilized under clinical care)
  • Diagnosed depersonalization-derealization disorder
  • Untreated post-traumatic stress disorder with active flashbacks (trauma-sensitive formats with a trained teacher only; never unsupervised silent practice)
Key Interactions
  • Antihypertensive medication (amlodipine, lisinopril, losartan, hydrochlorothiazide): Additive blood pressure lowering
  • Antidepressants (escitalopram, sertraline and other selective serotonin reuptake inhibitors): Unsupervised discontinuation risks relapse
  • Glucose-lowering agents (insulin; sulfonylureas such as glipizide): Hypoglycemia more likely on fixed doses
  • Sedatives and hypnotics (zolpidem, lorazepam, diazepam): Marked drowsiness during sessions
  • Over-the-counter sedating agents (diphenhydramine, doxylamine, melatonin): Additive drowsiness
  • Calming supplements (ashwagandha, L-Theanine, magnesium glycinate, valerian): Can mask whether practice is working
  • Blood-pressure-lowering supplements (beetroot nitrate, garlic extract, potassium): Additive; over-shoot in those already near target
  • Other interventions (psychedelic-assisted therapy, holotropic breathwork, floatation-based rest, extended fasting): Each destabilizes perception and arousal

Risk & Side Effects

  • High: Increased anxiety or depressive symptoms
    •
  • Medium: Dissociation and depersonalization; re-experiencing of traumatic memories
  • Low: Sleep disruption with intensive practice; reduced memory reliability; suicidal ideation and behavior; psychotic episodes in predisposed individuals
  • Speculative: Displacement of effective conventional treatment
    •

Monitoring

Marker Target Why
Seated blood pressure 110–120 / 70–78 mmHg The best-validated surrogate that meditation moves
Resting heart rate 50–65 bpm Tracks the autonomic shift toward parasympathetic tone
High-sensitivity C-reactive protein Below 1.0 mg/L General inflammation marker reported to fall in active-controlled trials
HbA1c 5.0–5.4% Detects whether reduced stress-hormone output is affecting glucose control
Morning cortisol (serum or salivary) 10–18 µg/dL serum at 08:00 The neuroendocrine marker with the most consistent meditation signal
DHEA-S Upper half of the age- and sex-specific reference range Indexes adrenal balance under chronic stress when read against cortisol
Heart rate variability (rMSSD) No established target; change from the individual's own 14-day baseline Session-level index of parasympathetic activation
Pittsburgh Sleep Quality Index 5 or below The sleep endpoint used in the trials showing benefit
Perceived Stress Scale 13 or below Captures the appraisal change meditation is proposed to produce
Anxiety and depression questionnaires 4 or below on each The two endpoints with the strongest supporting evidence

Cadence: Questionnaires at 4 and 8 weeks; blood pressure and resting heart rate every two weeks through the first 8 weeks; blood markers at 6 months and every 6–12 months thereafter.

Qualitative Assessment

  • Sleep onset latency and number of night wakings
  • Daytime energy and afternoon crash severity
  • Cognitive clarity — how often attention is lost mid-task
  • Reactivity — the lag between provocation and response
  • Adverse markers: detachment from self or surroundings, intrusive memories, unusual over-alertness
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.